Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

EASYGEN EASY workflow integration for GENe therapy

Coordinator
Fresenius Se & Co Kgaa, Germany
Runs
1 April 2025 to 31 March 2030
Status
Running
EU funding
€8.0m
Total cost
€12.9m
Partners
21 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101194710

What the project is doing

In the project's own words, from its summary on CORDIS.

More than 20 million new patients world-wide are diagnosed with cancer every year, and prediction for 2050 foresee over 35 million cancer cases, reflecting the population ageing and growth with a tremendous burden on the health care system. A global WHO survey with 115 participating countries has shown, that only 39% can cover basic cancer care management, financed as core health service. This reveals significant global inequities between high GNP and low- and middle-income countries, which is also reflected in country-specific cancer patient outcomes.

Hence, there is a strong need for emerging technologies, that democratize access to cancer treatment, reduce the disparities in cancer care, and significantly reduce the burden on the healthcare workforce. Chimeric Antigen Receptor T-cells are considered as cutting-edge treatment for cancer, but currently only for hematologic malignancies. And although the efficacy is very promising the number of European patients having access to CAR-T treatment is still very limited due to high costs and complex manufacturing and logistic processes.

The public private partnerhsip EASYGEN will develop an automated, modular point-of-care cell- and gene-therapy platform, that will allow for the first time hospital on-site CAR-T manufacturing. Designed as a closed, modular, one-stop solution, the device aims to reduce manufacturing time significantly to less than 24 hours and treatment costs by 50%. In a user-centric, co-creation approach, the device will be holistically integrated in a standard hospital workflow, hence empowering healthcare systems to provide CAR-T treatment in any standard hospital setting, capable of conducting leukapheresis.

Its modular set-up will ensure adaptability to different ATMPs including solid tumours. Therewith, EASYGEN will initiate a paradigm shift in the CAR-T market, paving the way to a greater democratized cancer treatment access and improving the patient’s quality of life and overall outcome.

Topics

Who is involved

OrganisationCityCountryRole
Fresenius Se & Co KgaaBad HomburgGermanyCoordinator
Cancer Patients EuropeBruxelles / BrusselBelgiumAssociatedpartner
Charles River Discovery Research Services Germany GmbHFreiburgGermanyParticipant
Frankfurt School of Finance & Management Gemeinnutzige GmbHFrankfurt Am MainGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Fresenius Kabi Deutschland GmbHBad HomburgGermanyAssociatedpartner
Helmholtz-Zentrum Dresden-Rossendorf eVDresdenGermanyParticipant
Helios Klinikum Berlin-Buch GmbHBerlinGermanyParticipant
Pro-Liance Global Solutions GmbHMunsterGermanyParticipant
T-Curx GmbHWurzburgGermanyAssociatedpartner
Tq Therapeutics GmbHMunchenGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Idcq Hospitales Y Sanidad SLMadridSpainAssociatedpartner
Universidad De NavarraPamplonaSpainParticipant
Cellix LimitedDublinIrelandParticipant
Bar Ilan UniversityRamat GanIsraelParticipant
European Society for Blood and Marrow TransplantationLeidenNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsParticipant
University of GlasgowGlasgowUnited KingdomParticipant
Fenwal IncLake ZurichUnited StatesParticipant
Kytopen Corp.CambridgeUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI